These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. Yassin DJ, Doros G, Hammerer PG, Yassin AA. J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761 [Abstract] [Full Text] [Related]
7. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. Permpongkosol S, Tantirangsee N, Ratana-olarn K. J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330 [Abstract] [Full Text] [Related]
8. [Evaluation of relationships between plasma androgens level and clinical signs of hipoandrogenism according to age and comorbidity of metabolic syndrome in men]. Herman WA, Krzoska A, Pawliczak E, Roszak M, Łacka K. Pol Merkur Lekarski; 2014 Jan; 36(211):16-21. PubMed ID: 24645572 [Abstract] [Full Text] [Related]
9. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. Schubert M, Jockenhövel F. J Endocrinol Invest; 2005 Jan; 28(3 Suppl):23-7. PubMed ID: 16042356 [Abstract] [Full Text] [Related]
10. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A, Blast Study Group. Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040 [Abstract] [Full Text] [Related]
11. Relative androgen deficiency in relation to obesity and metabolic status in older men. Chen RY, Wittert GA, Andrews GR. Diabetes Obes Metab; 2006 Jul; 8(4):429-35. PubMed ID: 16776750 [Abstract] [Full Text] [Related]
12. Risk factors for late-onset hypogonadism. Yang QT, Wu KS, Li ZJ, Li WC, Lu L, Wu HQ, Zhuang YY, Sui XX. Andrologia; 2018 Aug; 50(6):e13016. PubMed ID: 29665142 [Abstract] [Full Text] [Related]
13. Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies - a mini-review. Mäkinen JI, Huhtaniemi I. Gerontology; 2011 Aug; 57(3):193-202. PubMed ID: 20689266 [Abstract] [Full Text] [Related]
14. [Relevant clinical and biological criteria for the diagnosis of androgen deficiency in the aging male (ADAM)]. Seisen T, Rouprêt M, Gallais JL, Costa P. Prog Urol; 2012 Jun; 22 Suppl 1():S21-6. PubMed ID: 22770497 [Abstract] [Full Text] [Related]
15. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Lunenfeld B, Saad F, Hoesl CE. Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160 [Abstract] [Full Text] [Related]
16. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Diabetes Care; 2007 Apr; 30(4):911-7. PubMed ID: 17392552 [Abstract] [Full Text] [Related]
17. [Role of androgen in the elderly. What is LOH syndrome?]. Hisasue S, Horie S. Clin Calcium; 2013 Aug; 23(8):1101-7. PubMed ID: 23892209 [Abstract] [Full Text] [Related]
18. Are the Aging Male's Symptoms (AMS) scale and the Androgen Deficiency in the Aging Male (ADAM) questionnaire suitable for the screening of late-onset hypogonadism in aging Chinese men? Chen W, Liu ZY, Wang LH, Zeng QS, Wang HQ, Sun YH. Aging Male; 2013 Sep; 16(3):92-6. PubMed ID: 23862578 [Abstract] [Full Text] [Related]
20. Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism. Holm AC, Fredrikson MG, Theodorsson E, Palmefors LG, Karlsson PS, Joborn C, Hammar ML. Aging Male; 2011 Dec; 14(4):249-56. PubMed ID: 21627562 [Abstract] [Full Text] [Related] Page: [Next] [New Search]